Search hospitals

>

Washington

>

Tacoma

MultiCare Tacoma General Hospital

Claim this profile

Tacoma, Washington 98405

Global Leader in Breast Cancer

Global Leader in Ovarian Cancer

Conducts research for Lung Cancer

Conducts research for Breast cancer

Conducts research for Non-Small Cell Lung Cancer

258 reported clinical trials

7 medical researchers

Photo of MultiCare Tacoma General Hospital in TacomaPhoto of MultiCare Tacoma General Hospital in TacomaPhoto of MultiCare Tacoma General Hospital in Tacoma

Summary

MultiCare Tacoma General Hospital is a medical facility located in Tacoma, Washington. This center is recognized for care of Breast Cancer, Ovarian Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. MultiCare Tacoma General Hospital is involved with conducting 258 clinical trials across 359 conditions. There are 7 research doctors associated with this hospital, such as Jennifer Slim, Steven Phillips, John A. Keech, and Laila Rashidi, MD.

Area of expertise

1

Breast Cancer

Global Leader

MultiCare Tacoma General Hospital has run 36 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV
2

Ovarian Cancer

Global Leader

MultiCare Tacoma General Hospital has run 34 trials for Ovarian Cancer. Some of their research focus areas include:

Stage II
Stage III
Stage IV

Top PIs

Clinical Trials running at MultiCare Tacoma General Hospital

Lung Cancer

Pancreatic Carcinoma

Breast Cancer

Breast cancer

Non-Small Cell Lung Cancer

Cardiotoxicity

Multiple Myeloma

ALK Gene Rearrangement

Coronavirus

Vestibular Migraine

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

Recruiting

2 awards

Phase 3

28 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at MultiCare Tacoma General Hospital?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security